Table 2. Observed and Expected Cancer Risks and Standardized Incidence Ratios in 134 173 Patients With a First Hospital-Based Hematuria Diagnosis.
| Cancer Type | 0- to <3-mo Follow-up | 3-mo to <1-y Follow-up | 1- to <5-y Follow-up | ≥5-y Follow-up | ||||
|---|---|---|---|---|---|---|---|---|
| Cancers O/E, No. | SIR (95% CI) | Cancers O/E, No. | SIR (95% CI) | Cancers O/E, No. | SIR (95% CI) | Cancers O/E, No. | SIR (95% CI) | |
| Any cancer | 6425/454 | 14.15 (13.81-14.50) | 2356/1255 | 1.88 (1.80-1.96) | 6072/5096 | 1.19 (1.16-1.22) | 6604/5928 | 1.11 (1.09-1.14) |
| Urologic cancers | ||||||||
| Noninvasive bladder | 1077/4 | 242.62 (228.35-257.56) | 160/12 | 13.07 (11.12-15.26) | 162/65 | 2.97 (2.53-3.46) | 92/68 | 1.36 (1.10-1.67) |
| Kidney | 569/7 | 81.40 (74.85-88.37) | 119/19 | 6.14 (5.09-7.35) | 149/78 | 1.92 (1.63-2.26) | 127/87 | 1.46 (1.22-1.74) |
| Renal pelvic | 196/1 | 208.51 (180.34-239.84) | 63/3 | 24.35 (18.71-31.15) | 67/10 | 6.49 (5.03-8.25) | 23/12 | 1.96 (1.24-2.95) |
| Ureteral | 61/<1 | 178.04 (136.18-228.71) | 29/1 | 30.88 (20.68-44.35) | 24/4 | 6.54 (4.19-9.72) | 16/4 | 4.03 (2.30-6.54) |
| Prostate | 908/64 | 14.18 (13.27-15.13) | 371/176 | 2.11 (1.90-2.34) | 826/714 | 1.16 (1.08-1.24) | 880/802 | 1.10 (1.03-1.17) |
| Gynecologic cancers | ||||||||
| Uterine | 39/5 | 7.88 (5.61-10.78) | 42/14 | 2.99 (2.16-4.04) | 73/59 | 1.23 (0.97-1.55) | 60/76 | 0.79 (0.60-1.02) |
| Cervical | 23/2 | 10.19 (6.46-15.29) | 0/6 | NA | 17/26 | 0.66 (0.38-1.06) | 23/28 | 0.82 (0.52-1.23) |
| Ovarian | 21/4 | 5.48 (3.39-8.37) | 10/11 | 0.92 (0.44-1.69) | 44/45 | 0.97 (0.71-1.31) | 46/54 | 0.86 (0.63-1.14) |
| Abdominal cancers | ||||||||
| Colon | 122/33 | 3.73 (3.10-4.46) | 92/90 | 1.03 (0.83-1.26) | 353/359 | 0.98 (0.88-1.09) | 448/404 | 1.11 (1.01-1.22) |
| Rectal | 53/18 | 3.00 (2.24-3.92) | 40/49 | 0.82 (0.59-1.12) | 178/195 | 0.92 (0.79-1.06) | 163/214 | 0.76 (0.65-0.89) |
| Liver | 24/4 | 5.96 (3.82-8.87) | 18/11 | 1.63 (0.96-2.57) | 66/44 | 1.49 (1.15-1.89) | 57/50 | 1.14 (0.87-1.48) |
| Hematologic cancers | ||||||||
| Leukemia | 31/10 | 3.22 (2.19-4.58) | 39/26 | 1.48 (1.05-2.02) | 141/105 | 1.34 (1.13-1.58) | 143/116 | 1.24 (1.04-1.46) |
| Non-Hodgkin lymphoma | 60/11 | 5.58 (4.26-7.18) | 48/30 | 1.61 (1.19-2.14) | 133/119 | 1.11 (0.93-1.32) | 154/137 | 1.12 (0.95-1.32) |
| Multiple myeloma | 42/4 | 10.02 (7.22-13.54) | 25/12 | 2.17 (1.40-3.20) | 62/46 | 1.34 (1.03-1.72) | 68/52 | 1.30 (1.01-1.65) |
Abbreviations: O/E, observed vs expected; SIR, standardized incidence ratio.